Biogen (BIIB) Other Non Operating Income (2009 - 2015)
Biogen (BIIB) posted quarterly Other Non Operating Income of -$15.0 million for Q1 2015, down 167.56% year-over-year from $22.2 million in Q1 2014, and down 70.88% quarter-over-quarter from -$8.8 million in Q4 2014.
Biogen (BIIB) Other Non Operating Income (2009 - 2015) Analysis & Trends
Biogen's Other Non Operating Income history runs 7 years deep, the most recent figure standing at -$15.0 million for Q1 2015.
- In Q1 2015, Other Non Operating Income fell 167.56% year-over-year to -$15.0 million; the TTM figure through Mar 2015 stood at -$35.2 million (down 35.1% YoY), while the FY2016 annual figure was -$217.4 million, down 75.75% from the prior year.
- Other Non Operating Income for Q1 2015 stood at -$15.0 million, down from -$8.8 million in the prior quarter.
- The five-year high for Other Non Operating Income was $15.1 million in Q1 2012, with the low at -$17.4 million in Q1 2011.
- The 5-year median for Other Non Operating Income is -$5.6 million (2014), against an average of -$6.2 million.
- The sharpest annual moves came in 2012 and 2013: Other Non Operating Income surged 73850.0% in 2012, then tumbled 453.49% in 2013.
- Biogen's Other Non Operating Income stood at -$4.0 million in 2011, then plunged by 259.68% to -$14.3 million in 2012, then soared by 62.39% to -$5.4 million in 2013, then plunged by 63.16% to -$8.8 million in 2014, then slumped by 70.88% to -$15.0 million in 2015.
- Business Quant data shows BIIB's Other Non Operating Income at -$15.0 million in Q1 2015, -$8.8 million in Q4 2014, and -$16.3 million in Q3 2014.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Johnson & Johnson | 652.20 Bn | 631.44 Bn | 17.26 Bn |
| 2 | AbbVie | 469.51 Bn | 462.94 Bn | 12.70 Bn |
| 3 | Merck | 376.81 Bn | 369.67 Bn | 12.21 Bn |
| 4 | Novartis Ag | 303.04 Bn | 295.35 Bn | 11.24 Bn |
| 5 | Astrazeneca | 257.61 Bn | 252.71 Bn | 12.86 Bn |
| 6 | Amgen | 237.37 Bn | 223.38 Bn | 7.24 Bn |
| 7 | Gilead Sciences | 181.73 Bn | 178.55 Bn | 6.22 Bn |
| 8 | Pfizer | 159.66 Bn | 147.96 Bn | 10.94 Bn |
| 9 | Gsk | 106.24 Bn | 102.07 Bn | 8.24 Bn |
| 10 | Biogen | 32.04 Bn | 30.76 Bn | 1.96 Bn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2015 | -14.99 Mn |
| Dec 31, 2014 | -8.77 Mn |
| Sep 30, 2014 | -16.29 Mn |
| Jun 30, 2014 | 4.86 Mn |
| Mar 31, 2014 | -5.60 Mn |
| Dec 31, 2013 | -5.38 Mn |
| Sep 30, 2013 | -4.64 Mn |
| Jun 30, 2013 | -10.43 Mn |
| Mar 31, 2013 | -14.46 Mn |
| Dec 31, 2012 | -14.29 Mn |
| Sep 30, 2012 | -4.55 Mn |
| Jun 30, 2012 | 2.95 Mn |
| Mar 31, 2012 | 15.14 Mn |
| Dec 31, 2011 | -3.97 Mn |
| Sep 30, 2011 | -7.73 Mn |
| Jun 30, 2011 | -4,000.00 |
| Mar 31, 2011 | -17.38 Mn |
| Dec 31, 2010 | -4.70 Mn |
| Sep 30, 2010 | -6.90 Mn |
| Jun 30, 2010 | 1.00 Mn |